Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Aug 19;10(9):625.
doi: 10.1038/s41419-019-1859-8.

SIRT1-targeted miR-543 autophagy inhibition and epithelial-mesenchymal transition promotion in Helicobacter pylori CagA-associated gastric cancer

Affiliations

SIRT1-targeted miR-543 autophagy inhibition and epithelial-mesenchymal transition promotion in Helicobacter pylori CagA-associated gastric cancer

Yanyan Shi et al. Cell Death Dis. .

Abstract

Gastric cancer is an important cause of death worldwide with Helicobacter pylori (H. pylori) considered a leading and known risk factor for its development. More particularly and despite the underlying mechanisms not being very clear, studies have revealed that the H. pylori cytotoxin-associated gene A (CagA) protein plays a key role in this process. In this study it was found that H. pylori increased the expression of miR-543 in human gastric cancer tissue when compared with H. pylori-negative gastric cancer tissue samples. In vitro experiments showed that increased expression of miR-543 induced by CagA is a strong promoter of cell proliferation, migration, and invasion. Conversely, a miR-543 inhibitor suppressed or reversed these effects. It was furthermore found that silencing miR-543 inhibited autophagy and led to epithelial-mesenchymal transition (EMT) under in vitro. The mechanisms by which miR-543 targets SIRT1 to downregulate autophagy was also described. The results suggest that in the progression of H. pylori-associated gastric cancer, CagA induces overexpression of miR-543, which subsequently targets SIRT1 to suppress autophagy. This may be followed by increased expression of EMT causing cell migration and invasion. Consequently, miR-543 might be considered a therapeutic target for H. pylori-associated gastric cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1. H. pylori CagA increased expression of miR-543.
a RT-PCR results of miR-543 expression. b RT-PCR results of SIRT1 expression. c IHC experiments of CagA and SIRT1 in normal gastric tissue; HP+ or HP−. d Quantified IHC results. e Western blot results of SIRT1 in tumor tissues; HP+ or HP−. f Quantified western blot results. g Western blot results of CagA and VacA in AGS, SNU1, MGC-803, and MKN1; infected with strain 60190 or 26695. h RT-PCR results of miR-543 in AGS, SNU1, MGC-803, or MKN1 cell lines after infected with H. pylori CagA+ strain 26695 in different hours. i RT-PCR results of CagA in AGS, SNU1, MGC-803, or MKN1 cell lines after infected with H. pylori CagA+ or CagA− strain in 24 h. j RT-PCR results of miR-543 in AGS, SNU1, MGC-803, or MKN1 cell lines after infected with H. pylori CagA+ or CagA− strain in 24 h. k RT-PCR results of miR-543 in GES-1, AGS, SNU1, MGC-803, or MKN1 cells. Data are expressed as the mean ± SD (n = 3). **P < 0.01, ***P < 0.001 compared with control
Fig. 2
Fig. 2. miR-543 overexpression promoted the accelerating effect of CagA+ H. pylori on cell proliferation.
a RT-PCR results of miR-543 expression in MGC-803 and MKN1 cells transfected with pCDH-miR-543 vectors or AGS and SNU1 transfected with the anti-miR-543 vector; infected with HP or not. b CCK-8 cell proliferation analyses of MGC-803 (HP (CagA+) or pCDH-miR-543 or both HP (CagA+) and pCDH-miR-543), MKN1 (HP (CagA+) or pCDH-miR-543 or both HP (CagA+ ) and pCDH-miR-543), AGS (HP (CagA+) or anti-miR-543 or both HP (CagA+) and anti-miR-543), and SNU1 (HP (CagA+) or anti-miR-543 or both HP (CagA+) and anti-miR-543). c AV-FITC staining apoptosis results of four kinds of cell lines processed as shown in Fig. 2c. d Quantitative analysis of apoptosis. e Colony formation cell proliferation analyses results. f Quantitative analysis of cell proliferation. Data are expressed as the mean ± SD (n = 3). **P < 0.01, ***P < 0.001 versus control group; ##P < 0.01, ###P < 0.001 versus CagA+ HP group
Fig. 3
Fig. 3. Promotion of cell migration, invasion, and EMT was increased by miR-543 overexpression in CagA + H. pylori cells.
a Transwell chamber results of MGC-803 (HP (CagA+) or both HP (CagA+) and pCDH-miR-543), MKN1 (HP (CagA+) or both HP (CagA+) and pCDH-miR-543), AGS (HP (CagA+) or both HP (CagA+) and anti-miR-543), and SNU1 (HP (CagA+) or both HP (CagA+) and anti-miR-543). b Quantitative analysis of cell migration and invasion of four kinds of cell lines processed as shown in Fig. 3a. c Western blot results of EMT-related N-cadherin, E-cadherin, Snail, and Vimentin proteins. d Quantified western blot results and RT-PCR results of EMT-related genes. Data are expressed as the mean ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 versus control group; #P < 0.05, ##P < 0.01, ###P < 0.001 versus CagA+HP group
Fig. 4
Fig. 4. SIRT1 is a direct target of miR-543.
a Complementary sequences between miR-543 and the 3ʹ-UTR of SIRT1 or a mutated version of SIRT1 were obtained using publicly available algorithms. b Dual-luciferase reporter assays of SNU1 and AGS transfected by a mimic of miR-543 (with SIRT1-WT or SIRT1-MUT). c, d Western blot results of SIRT1 and quantified. e RT-PCR detection of SIRT1 expression in MGC-803 and MKN1 cells transfected with pCDH-miR-543, or AGS, and SNU1 cells transfected with anti-miR-543. Data are expressed as the mean ± SD (n = 3). ***P < 0.001 versus control group
Fig. 5
Fig. 5. SIRT1 was targeted by miR-543 to suppress cell proliferation, migration and invasion.
a RT-PCR analyses of SIRT1 in AGS and SNU1 cells transfected with anti-miR-543, siSIRT1, or both anti-miR-543 and siSIRT1. b CCK-8 cell proliferation analyses of AGS and SNU1 cells transfected with anti-miR-543, siSIRT1, or both anti-miR-543 and siSIRT1. Autophagy enhancer RAPA addition and siSIRT1 transfection results were also studied and compared. c Colony formation assays show the results of cell proliferation. d Quantitative analysis of colony formation. e Transwell chamber experiments on cell migration and invasion. f Quantitative results of migration and invasion. g RT-PCR detection of N-cadherin, E-cadherin, and Snail proteins in AGS and SNU1 cells. h, i Western blot detection of N-cadherin, E-cadherin, Vimentin, and Snail in AGS and SNU1 cells and quantified. Data are expressed as the mean ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 versus control group; #P < 0.05, ##P < 0.01, ###P < 0.001 versus siSIRT1 group
Fig. 6
Fig. 6. SIRT1 was targeted by miR-543 to suppress autophagy.
a Detection of autophagy using mRFP-GFP-LC3 in AGS and SNU1 cells transfected with anti-miR-543, siSIRT1, or both anti-miR-543 and siSIRT1. Green puncta indicate the autophagosomes, while the red puncta represent the autolysosomes. Autophagy enhancer RAPA addition and siSIRT1 transfection results were also studied and compared. b Quantitative analysis of mRFP-GFP-LC3 detection. c The autophagic vacuoles (autophagosomes) were detected by transmission electron microscopy (TEM). The representative TEM images are shown and the typical autophagosomes are marked with arrows. d Quantitative analysis of autophagy detection by TEM. e, f Western blot detection of autophagy-related proteins LC3-I, LC3-II, and p62 and Quantified. Data are expressed as the mean ± SD (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 versus control group; #P < 0.05, ##P < 0.01, ###P < 0.001 versus siSIRT1 group
Fig. 7
Fig. 7. SIRT1 was targeted by miR-543 to suppress autophagy in vivo.
a Rapid urease test of H. pylori infection on C57BL/6 mice. b Hematoxylin-eosin staining image of control and HP (CagA+) group in mice gastric epithelium. c, d Western blot detection of SIRT1 and autophagy-related proteins LC3-I, LC3-II, and p62 and quantified. Data are expressed as the mean ± SD (n = 8). **P < 0.01, ***P < 0.001 versus control group; #P < 0.05, ##P < 0.01, ###P < 0.001 versus HP(CagA+) group, $$P < 0.01, $$$P < 0.001 versus HP(CagA+) + miR-543 inhibitor group

Similar articles

Cited by

References

    1. Torre LA, et al. Global cancer statistics, 2012. CA Cancer J. Clin. 2015;65:69–90. doi: 10.3322/caac.21262. - DOI - PubMed
    1. Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2018;68:394–424. doi: 10.3322/caac.21492. - DOI - PubMed
    1. Polk, D. B. & Peek, R. M. Jr. Helicobacter pylori: gastric cancer and beyond. Nat. Rev. Cancer10, 403–414 (2010). - PMC - PubMed
    1. Cover TL, Blaser MJ. Helicobacter pylori in health and disease. Gastroenterology. 2009;136:1863–1873. doi: 10.1053/j.gastro.2009.01.073. - DOI - PMC - PubMed
    1. Angelo Z, Cesare H, Sergio M. Helicobacter pylori infection and the development of gastric cancer. New Engl. J. Med. 2002;346:65. doi: 10.1056/NEJM200201033460115. - DOI - PubMed

Publication types

MeSH terms